Sponsor pipeline

Shanghai Pulmonary Hospital, Shanghai, China clinical trial pipeline

Get alerts when Shanghai Pulmonary Hospital, Shanghai, China's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

  1. Minor

    Completed without a posted recruiting period

    Also in this update: Primary completion date changed from estimate of Sep 1, 2030 to Aug 29, 2026

    Shanghai Pulmonary Hospital, Shanghai, ChinaPhase 2 NCT06648200 Registry history

    Updated

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-15 NCT07874581 Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC Recruiting
2026-10-13 NCT07870733 Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm… Not Yet Recruiting
2026-10-07 NCT07863999 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With… Phase 3 Recruiting
2026-09-16 NCT07823842 T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in… Recruiting

Active trials by phase

Phase 2
40
Phase 3
5
Phase 4
5
Not charted: 29 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 79

NCT IDTitleConditionStatusUpdated
Phase 4
NCT07754812 Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment… NSCLC (Non-small Cell Lung Cancer) Recruiting 2026-08-10
NCT05493267 A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB MDR-TB Recruiting 2022-08-10
NCT07469488 A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM)… NSCLC (Advanced Non-small Cell Lung Cancer) Not Yet Recruiting 2026-03-13
NCT07393386 Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally… Pain Management Not Yet Recruiting 2026-02-06
NCT07141810 Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic… Fibrotic Interstitial Lung Disease Not Yet Recruiting 2025-08-26
Phase 3
NCT07863999 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With… Locally Advanced Non-Small Cell Lung Cancer Recruiting 2026-10-07
NCT07608159 Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. Non Small Cell Lung Cancer Not Yet Recruiting 2026-05-29
NCT07169903 Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A… Lung Adenocarcinoma Not Yet Recruiting 2025-09-12
NCT05496166 The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and… Limited Stage Small Cell Lung Cancer Not Yet Recruiting 2023-05-17
NCT04772287 Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2)… Non Small Cell Lung Cancer Not Yet Recruiting 2021-02-26
Phase 2
NCT06019468 Neoadjuvant Treatment For Locally Advanced Thymic Cancer Thymic Carcinoma Recruiting 2026-05-08
NCT07408635 IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in… Unresectable Stage III Non-small Cell Lung Cancer Recruiting 2026-02-13
NCT07410975 Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant… NSCLC Stage II Recruiting 2026-02-13
NCT07323056 Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ… EGFR-mutant Non-small Cell Lung Cancer Recruiting 2026-01-07
NCT06758700 Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung… Extensive-stage Small Cell Lung Cancer (ES-SCLC) Recruiting 2025-12-05
NCT06987734 Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With… Lung Cancer (NSCLC) Recruiting 2025-06-26
NCT06749860 Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical… Lung Cancer Recruiting 2024-12-27
NCT06749886 An Exploratory Study of Tislelizumab in Combination with Chemotherapy in… Lung Cancer Recruiting 2024-12-27
NCT05766800 Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy… Locally Advanced Recruiting 2024-09-19
NCT06528847 Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma Non-Small Cell Lung Cancer Recruiting 2024-07-31
NCT06256237 Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum… Limited Stage Small Cell Lung Cancer Recruiting 2024-05-29
NCT04728724 Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer Non-small Cell Lung Cancer Stage III Recruiting 2023-09-13
NCT04539977 PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage… Small-cell Lung Cancer Recruiting 2023-05-09
NCT05503667 Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable… Lung Adenocarcinoma Stage III Recruiting 2022-08-17
NCT05053802 Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients… Multiple Primary Lung Cancer Recruiting 2021-09-23
See all 79 active Shanghai Pulmonary Hospital, Shanghai, China trials with filters →

Disease areas by active trials

Lung Cancer (64) · Non-Small Cell Lung Cancer (NSCLC) (43) · Small Cell Lung Cancer (9) · Asthma (1) · COPD (1) · Idiopathic Pulmonary Fibrosis (1)

Get alerts when Shanghai Pulmonary Hospital, Shanghai, China's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free